As such, measuring the effect of sodium channel inhibitors on NaV1.6 channels and monitoring for adverse effects on respiration should be a key consideration when developing sodium channel inhibitors for the treatment of pain or epilepsy. This evidence concerns the gene SCN8A and epilepsy.